• HBV vaccination for rheumatism: ideal before biologics treatment

    Researchers investigated the immune response to HBV vaccination in patients with rheumatic diseases treated with biologics. Results are promising.

  • Thinking minds, guilty thoughts, and the guillotine debate

    The guillotine intended to avoid unnecessary agony in an execution. Was death instant though? We check if this question was settled, or not.

  • Interview: The future of gastrointestinal oncology

    This interview after the 'ESMO GI Cancers 2024' congress was an opportunity for in-depth study and discussion of new developments in GI oncology.

  • Treating GI tumours in geriatric patients

    Gastrointestinal tumours occur most frequently in people over 70. But how does the treatment of geriatric patients differ from that of younger patients?

  • Salmonella infection: is tomato juice a treatment option?

    Could bacteria or viruses be rendered harmless by tomatoes or its products? Researchers investigated if tomato substances work against S. typhi.

  • The effect of puberty onset on cardiovascular risk

    Is an earlier onset of puberty and hormone fluctuations associated with an increased cardiometabolic risk in adulthood?

  • Amblyopia in childhood: a risk factor later in life

    The link between childhood amblyopia and later cardiometabolic dysfunction has been known for some time But how high is amblyopia's risk?

  • Could poor air quality in aeroplanes pose health risks?

    The air you breathe in aircrafts is routinely contaminated by small amounts of engine oils and hydraulic fluids. Could these pollutants be harmful?

  • Gynaecological oncology: present and future

    During the ESMO Congress on Gynaecological Cancers, Prof. Scambia analysed developments in the field, and what's next in the coming decade.

  • Colon carcinoma: current biomarker tools and new developments

    Precision medicine is revolutionising treatments for colon cancer and other gastrointestinal malignancies by identifying biomarkers for personalised therapies.

  • New targets in immunotherapy

    New immunotherapies go beyond CTLA-4 and PD(L)1 and show promising results for treating various types of cancer, including colorectal cancer.

  • The Margarita Burn: A summer holiday phytophotodermatitis

    Summer season is coming, and with it, time by the pool; but also possibly some more cases of “Margarita burn” or phytophotodermatitis.

  • Survival benefits: haemodiafiltration outperforms haemodialysis

    In a first, haemodiafiltration was shown to have a lower risk of death than haemodialysis. Results could change current dialysis practice.

  • First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL

    The combination was associated with deep and durable responses in previously untreated high-risk CLL, SLL, and del(17p) and/or TP53 mutations.

  • Clinically meaningful outcomes for mosunetuzumab across FL subgroups

    High-risk participants with heavily pre-treated relapsed or refractory follicular lymphoma benefitted in clinical remission and survival outcomes.

  • AUGMENT-101: revumenib trial in KMT2Ar leukaemia stopped early for efficacy

    In a heavily pretreated population of participants with KMT2A rearranged acute leukaemia, revumenib displayed encouraging anti-tumour activity.

  • ESLIM-01: Sovleplenib delivers durable responses and QoL improvements in primary ITP

    Sovleplenib was associated with early and durable platelet responses in participants with primary immune thrombocytopenia.

  • Traffic noise could contribute to cardiovascular diseases

    Harmful environmental influences, such as air and noise pollution or light pollution at night, can also contribute to susceptibility to disease.

  • RUBY: Promising data for first AsCas12a gene-editing therapy in sickle cell disease

    Renizgamglogene autogedtemcel (reni-cel) established a swift and durable normalisation in haemoglobin and improvements in haemolysis markers.

  • Excellent phase 3 results for asciminib in CML

    Asciminib was superior to all other tested first-line tyrosine kinase inhibitors (TKIs) in participants with chronic myeloid leukaemia (CML).

  • 2 |
  • 3 |
  • 4 |
  • 5 |
  • 6 |
  • 7 |
  • 8 |
  • 9 |
  • 10 |
  • 11 |
  • 12 |